Whether on your bank’s website or your telephone provider’s help line, interactions between humans and chatbots have become part of our daily lives. But do we trust them? And what factors influence our trust? Researchers at the University of Basel recently examined these questions.
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, which often leads to vision loss. Their study shows promising results using a precise technique for gene correction.
It’s once again time for one of the most famous stories in the Bible. But what is actually being told – and how? We're joined by theology professor Moisés Mayordomo to take a look at the story of the birth of Jesus and how biblical narratives work.
How can we ensure that as many Swiss households as possible adopt not only solar panels, but also their own battery to store solar energy, a heat pump, and an electric car? Researchers at the Universities of Basel and Geneva have looked into just this question.
Start-up Cimeio Therapeutics intends to pave the way for gentler and more efficient treatments for diseases such as blood cancer. The company, a spin-off of the University of Basel, has just concluded an important collaboration agreement: Cimeio is joining forces with the pharmaceutical firm Kyowa Kirin. Kyowa Kirin will be financing the collaboration with Cimeio with up to CHF 263 million.
Opinions differ on the issue of the coin: some find small change annoying, others collect coins. Rahel C. Ackermann deals with coins in her research. In this interview, the archaeologist and numismatist explains why they are worth a closer look, and how closely coins and customs are intertwined.
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions like schizophrenia or depression.
Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.
A research team from the University of Basel has succeeded in synthesizing simple, environmentally sensitive cells complete with artificial organelles. For the first time, the researchers have also been able to emulate natural cell-cell communication using these protocells – based on the model of photoreceptors in the eye. This opens up new possibilities for basic research and applications in medicine.
